Jason J. Luke, MD, FACP

According to Jason Luke, MD, FACP, there is still room to improve response rates in CSCC treatment, but there is excitement surrounding future of treatment outcomes.

Objective response data from the CK-301-101 trial supports cosibelimab’s approval by the FDA, according to Jason J. Luke, MD, FACP.

CancerNetwork® sat down with Jason Luke, MD, at the 2021 European Society for Medical Oncology Congress to talk about the latest developments in the use of immunotherapy for metastatic disease.

CancerNetwork spoke with Jason Luke, MD, FACP, at the SMR Conference regarding the latest updates on melanoma.

The unprecedented improvements in melanoma therapeutics over a short period of time have been nothing short of extraordinary. It may be that we are now on a road to cure, but surely the destination is not yet in sight.